Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease

Alexander, 2009, Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I, J. Lipid Res., 50, 1409, 10.1194/jlr.M800578-JLR200 Alexander, 2009, Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano, Arterioscler. Thromb. Vasc. Biol., 29, 1496, 10.1161/ATVBAHA.109.191379 Bielicki, 2002, Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I, Biochemistry, 41, 2089, 10.1021/bi011716p Cimmino, 2009, Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano), J. Cell Mol. Med., 13, 3226, 10.1111/j.1582-4934.2008.00614.x DeMattos, 2001, Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 98, 8850, 10.1073/pnas.151261398 Duyckaerts, 2009, Classification and basic pathology of Alzheimer disease, Acta Neuropathol., 118, 5, 10.1007/s00401-009-0532-1 Eikelenboom, 2010, Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease, Neurodegener. Dis., 7, 38, 10.1159/000283480 Fagan, 2004, ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis, Am. J. Pathol., 165, 1413, 10.1016/S0002-9440(10)63399-8 Fitz, 2015, Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice, Brain, 138, 3699, 10.1093/brain/awv293 Franceschini, 1999, Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice, Arterioscler. Thromb. Vasc. Biol., 19, 1257, 10.1161/01.ATV.19.5.1257 Franceschini, 1980, A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family, J. Clin. Invest., 66, 892, 10.1172/JCI109956 Ghiso, 1993, The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex, Biochem. J., 293, 27, 10.1042/bj2930027 Giannarelli, 2012, Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term, Thromb. Haemost., 108, 1246, 10.1160/TH12-08-0556 Greenberg, 1995, Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy, Ann. Neurol., 38, 254, 10.1002/ana.410380219 Han, 2011, Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy, Mol. Neurodegener., 6, 86, 10.1186/1750-1326-6-86 Handattu, 2009, Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease, Neurobiol. Dis., 34, 525, 10.1016/j.nbd.2009.03.007 Harr, 1996, Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease, J. Neurochem., 66, 2429, 10.1046/j.1471-4159.1996.66062429.x Hartmann, 2001, Cholesterol, A beta and Alzheimer's disease, Trends Neurosci., 24, 45, 10.1016/S0166-2236(01)00008-X Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 Ibanez, 2012, Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type), Atherosclerosis, 220, 72, 10.1016/j.atherosclerosis.2011.10.006 Ibanez, 2008, Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis, J. Am. Coll. Cardiol., 51, 1104, 10.1016/j.jacc.2007.09.071 Kallend, 2016, A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease, Eur. Heart J. Cardiovasc. Pharmacother., 2, 23, 10.1093/ehjcvp/pvv041 Kanekiyo, 2014, Bu G.ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?, Neuron, 81, 740, 10.1016/j.neuron.2014.01.045 Kaul, 2004, Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex, J. Am. Coll. Cardiol., 44, 1311, 10.1016/j.jacc.2004.06.028 Kawano, 1995, Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease, Clin. Chim. Acta, 239, 209, 10.1016/0009-8981(95)06115-T Kempen, 2016, High-density lipoprotein subfractions and cholesterol efflux capacities after infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in healthy volunteers and stable coronary artery disease patients, Arterioscler. Thromb. Vasc. Biol., 36, 736, 10.1161/ATVBAHA.115.307052 Kempen, 2014, Incubation of MDCO-216 (ApoA-IMilano/POPC) with human serum Potentiates ABCA1-mediated cholesterol efflux capacity, generates new Prebeta-1 HDL, and causes an increase in HDL size, J. Lipids, 2014, 923903 Koldamova, 2005, Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice, J. Biol. Chem., 280, 43224, 10.1074/jbc.M504513200 Koldamova, 2001, Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity, Biochemistry, 40, 3553, 10.1021/bi002186k Koudinov, 1998, Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids, Clin. Chim. Acta, 270, 75, 10.1016/S0009-8981(97)00207-6 Lefterov, 2010, Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice, J. Biol. Chem., 285, 36945, 10.1074/jbc.M110.127738 Lewis, 2010, Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease, J. Biol. Chem., 285, 36958, 10.1074/jbc.M110.127829 Ma, 2012, Tweaking the cholesterol efflux capacity of reconstituted HDL, Biochem. Cell Biol., 90, 636, 10.1139/o2012-015 Merched, 2000, Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease, Neurobiol. Aging, 21, 27, 10.1016/S0197-4580(99)00103-7 Merino-Zamorano, 2016, Modulation of amyloid-β1-40 transport by ApoA1 and ApoJ across an in vitro model of the blood-brain barrier, J. Alzheimers Dis., 53, 677, 10.3233/JAD-150976 Mineo, 2012, Novel biological functions of high-density lipoprotein cholesterol, Circ. Res., 111, 1079, 10.1161/CIRCRESAHA.111.258673 Minett, 2016, Microglial immunophenotype in dementia with Alzheimer's pathology, J. Neuroinflammation, 13, 135, 10.1186/s12974-016-0601-z Montañola, 2016, Hernández-Guillamon M.ApoA1, ApoJ and ApoE plasma levels and genotype frequencies in cerebral amyloid angiopathy, Neuromolecular Med., 18, 99, 10.1007/s12017-015-8381-7 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Paula-Lima, 2009, Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity, Int. J. Biochem. Cell Biol., 41, 1361, 10.1016/j.biocel.2008.12.003 Reitz, 2010, Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease, Arch. Neurol., 67, 1491, 10.1001/archneurol.2010.297 Robert, 2016, Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice, Biochim. Biophys. Acta, 1862, 1027, 10.1016/j.bbadis.2015.10.005 Saczynski, 2007, The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study, Am. J. Epidemiol., 165, 985, 10.1093/aje/kwm027 Schmechel, 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 9649, 10.1073/pnas.90.20.9649 Shah, 1998, Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice, Circulation, 97, 780, 10.1161/01.CIR.97.8.780 Sirtori, 2001, Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study, Circulation, 103, 1949, 10.1161/01.CIR.103.15.1949 Solomon, 2009, Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later, Dement. Geriatr. Cogn. Disord., 28, 75, 10.1159/000231980 Speidl, 2010, Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model, Eur. Heart J., 31, 2049, 10.1093/eurheartj/ehq064 Stukas, 2014, High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease, Cell Metab., 19, 574, 10.1016/j.cmet.2014.01.003 Sturchler-Pierrat, 1997, Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc. Natl. Acad. Sci. U. S. A., 94, 13287, 10.1073/pnas.94.24.13287 Thanopoulou, 2010, SR-BI regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model, Proc. Natl. Acad. Sci. U. S. A., 107, 20816, 10.1073/pnas.1005888107 Vagelatos, 2013, Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship, Epidemiol. Rev., 35, 152, 10.1093/epirev/mxs012 van Oijen, 2007, Atherosclerosis and risk for dementia, Ann. Neurol., 61, 403, 10.1002/ana.21073 Wahrle, 2005, Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem., 280, 43236, 10.1074/jbc.M508780200 Weibel, 2007, Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux, Arterioscler. Thromb. Vasc. Biol., 27, 2022, 10.1161/ATVBAHA.107.148403 Weisgraber, 1983, Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I, J. Biol. Chem., 258, 2508, 10.1016/S0021-9258(18)32955-7 Weksler, 2005, Blood-brain barrier-specific properties of a human adult brain endothelial cell line, FASEB J., 19, 1872, 10.1096/fj.04-3458fje Yardeni, 2011, Retro-orbital injections in mice, Lab Anim. (NY), 40, 155, 10.1038/laban0511-155